Location History:
- Helsinki, FI (2000 - 2004)
- Siuntio, FI (2005)
Company Filing History:
Years Active: 2000-2005
Title: Jukka Vidgren: Innovator in Pharmaceutical Chemistry
Introduction
Jukka Vidgren is an accomplished inventor based in Helsinki, Finland, with a significant contribution to the field of pharmaceutical chemistry. With four patents to his name, Jukka has made notable strides in innovation that may aid in the development of effective therapies.
Latest Patents
Among his latest inventions, Jukka has developed coumarin derivatives that exhibit COMT (Catechol-O-Methyltransferase) inhibiting activity. These compounds, defined by their unique formula, showcase two hydroxyl (-OH) substituents positioned ortho to one another in the phenyl moiety. This innovative approach signifies a potential breakthrough in targeted therapies as COMT inhibitors.
Another noteworthy patent involves compounds designed to deactivate phospholamban function on Ca-ATPase, identifying a three-dimensional structure of the cytosolic domain of phospholamban through high-resolution NMR data. This invention not only facilitates rational drug design but also provides methods enabling the creation of phospholamban inhibitors that have specific structural and physicochemical characteristics for effective interaction with the active site.
Career Highlights
Throughout his professional journey, Jukka has contributed his expertise to Orion Corporation and Orion-yhtyma Oy, where he has played a vital role in the research and development of pharmaceutical innovations. His work reflects a commitment to enhancing medical treatment options through scientific advancements.
Collaborations
Jukka Vidgren has collaborated with esteemed colleagues Timo Lotta and Martti Ovaska. Their combined efforts have proved instrumental in nurturing a productive research environment, promoting innovation in pharmaceutical sciences.
Conclusion
Jukka Vidgren stands as a testament to the impact inventors can have in the realm of pharmacology. His innovative patents and collaborations highlight a promising future in drug development, paving the way for potential treatments that could benefit many.